Biolife Solutions Inc(BLFS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 5:21 AM ET (Korea 9/15 18:21)
Full metrics table
| Index | RUT | P/E | 36.64 | EPS (ttm) | 0.97 | Insider Own | 2.98% | Shs Outstand | 48.9M | Perf Week | 0.51% |
| Market Cap | 1.73B | Forward P/E | 113.56 | EPS next Y | -48% | Insider Trans | -45.2% | Shs Float | 47.5M | Perf Month | 0.57% |
| Enterprise Value | 1.67B | PEG | - | EPS next Q | 0.05 | Inst Own | 95.13% | Short Float | 8.27% | Perf Quarter | 35.75% |
| Income | 0.05B | P/S | 16.86 | EPS this Y | 340% | Inst Trans | -6.15% | Short Ratio | 3.46 | Perf Half Y | 92.97% |
| Sales | 0.10B | P/B | 4.12 | EPS next 5Y | - | ROA | 12.09% | Short Interest | 3.93M | Perf YTD | 46.53% |
| Book/sh | 8.59 | P/C | 21.03 | EPS past 3/5Y | 54.38% -55.02% | ROE | 13.15% | 52W High | -7.01% ($38.10) | Perf Year | 38.89% |
| Cash/sh | 1.68 | P/FCF | 213.73 | Sales past 3/5Y | -15.9% 14.88% | ROIC | 11% | 52W Low | 98.38% ($17.86) | Perf 3Y | 159.56% |
| Dividend Est. | - | EV/EBITDA | 260.01 | EPS Y/Y TTM | 981.57% | Gross Margin | 64.76% | Volatility(W/M) | 2.36% 2.7% | Perf 5Y | -30.61% |
| Dividend TTM | - | EV/Sales | 16.21 | Sales Y/Y TTM | 0.17% | Oper. Margin | 2.9% | ATR (14) | 0.99 | Perf 10Y | 1890.45% |
| Dividend Ex-Date | - | Quick Ratio | 7.14 | EPS Q/Q | 376.1% | Profit Margin | 46.35% | RSI (14) | 54.53 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.69 | Sales Q/Q | 11.98% | SMA20 | -1.69% ($36.04) | Beta | 1.84 | Target Price | $31.12 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/6 | SMA50 | 7.13% ($33.07) | Rel Volume | 0.46 | Prev Close | $34.95 |
| Employees | 155 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 2807.35% 2.41% | SMA200 | 37.89% ($25.69) | Avg Volume(3M) | 1.14M | Price | $35.43 |
| IPO | 1989/11/22 | Option/Short | Yes/Yes | Trades | 5043 | Volume | 524,524 | Change | 1.37% |
Company
BLFS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 BioLife Solutions (BLFS) is a U.S. healthcare company that develops, manufactures, and sells bioprocessing tools and services for the cell and gene therapy industry. Centered on its core biopreservation (cryopreservation) media products, the company combines controlled-rate freezing and thawing systems with storage services to provide an infrastructure that supports the entire production, shipping, and storage process for cell therapies.
Over the past 1 year, on the higher side
7% below its 1-year high.
BLFS makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +340.0% this year.
Tap to view numbers
But it is not cheap
Trading at 36.6 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is negative
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by +159.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 95.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SGRW 0.01%
SMAP 0.01%
AIMS 0.01%
SMIZ 0.01%
MIC 0.01%It ranks #4 in the industry
Based on market cap of $2B.
BLFS $2B PER 36.6
ISRG $134B PER 43.3
BDX $50B PER 55.2
MDLN $43B PER 38.2
FAQ
What kind of company is BLFS?
BLFS belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of BLFS?
The market cap of BLFS is approximately $1.7B, ranking 2,226 within its sector.
What is the P/E ratio of BLFS?
BLFS has a P/E ratio of approximately 36.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BLFS?
BLFS has recorded a 52-week high of $38.10 and a low of $17.86.
